85-1958-64　Noggin, Recombinant, Human (NOG) 5ug　149600

特徴

• Noggin belongs to a group of diffusible proteins which bind to ligands of the TGF-b family and regulate their activity by inhibiting their access to signaling receptors. The interplay between TGF-b ligands and their natural antagonists has major biological significance during development processes, in which cellular response can vary considerably depending upon the local concentration of the signaling molecule. Noggin was originally identified as a BMP-4 antagonist whose action is critical for proper formation of the head and other dorsal structures. Consequently, Noggin has been shown to modulate the activities of other BMPs including BMP-2,-7,-13, and -14. Targeted deletion of Noggin in mice results in prenatal death and recessive phenotype displaying a severely malformed skeletal system. Conversely, transgenic mice over-expressing Noggin in mature osteoblasts display impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis. Recombinant human Noggin is a 46kD disulfide-linked homodimer (120-10C) consisting of two 206aa polypeptide chains. Monomeric glycosylated Noggin migrates at an apparent molecular weight of approximately 28-33kD by SDS PAGE analysis under reducing conditions.
• Source:Recombinant protein corresponding to human Noggin, expressed in 293 cells.
• Biological Activity:Determined by its ability to inhibit 5ng/ml of BMP-4 induced alkaline phosphatase production by ATDC chondrogenic cells. The expected ED50 for this effect is 2-3ng/ml of Noggin.
• Endotoxin:<0.1ng/ug (1EU/ug)
• AA Sequence:QHYLHIRPAP SDNLPLVDLI EHPDPIFDPK EKDLNETLLR SLLGGHYDPG FMATSPPEDR PGGGGGAAGG AEDLAELDQL LRQRPSGAMP SEIKGLEFSE GLAQGKKQRL SKKLRRKLQM WLWSQTFCPV LYAWNDLGSR FWPRYVKVGS CFSKRSCSVP EGMVCKPSKS VHLTVLRWRC QRRGGQRCGW IPIQYPIISE CKCSC
• Storage and Stability:May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.